slides · global inventory
Table
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 60,557
Current window 44,431-44,460
Pages 2,019
Rows per page 30
Component
44,431-44,460 of 60,557
04
The slide uses a custom timeline/pipeline layout to show drug development stages.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
11
The slide outlines a multi-part clinical trial process from Part A (Safety) through Part B (Efficacy/Dose Selection) to a planned Expansion phase.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
12
The table compares a standard of care (Cyramza), a regulatory benchmark, and the company's own drug candidate (THIO-101).MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
13
Data cut of ongoing study THIO-101 as of 13Nov2023.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
15
Data cut as of 13Nov2023.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
26
The slide contrasts the massive combined market of established CPIs ($42B) with the smaller market share of Libtayo ($0.5B) to frame the opportunity for partnership/growth.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Market Size1 hit
27
The slide uses market cap data to establish valuation benchmarks and cites recent M&A activity as a validation of the sector's value.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Competition1 hit
28
The slide uses a grid-based timeline layout to map specific clinical events to calendar years.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
30
Includes details on options, warrants, and insider ownership percentages.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
14
The table compares two distinct clinical trials (ColoFuture and eAArly DETECT) across key performance metrics.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
22
Includes income statement metrics, balance sheet data, and equity structure.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
08
Uses a before-after-bridge style logic to frame the solution.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
19
The slide uses a matrix-like structure to map disease areas (Infection, Inflammation, Oncology) to specific animal models and clinical indications.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
04
Includes a specific note regarding the effective income tax rate increase.Matson | Results Presentation Deck | 10 slides · Matson
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
03
The slide uses a matrix-like structure to compare financial metrics over time, with donut charts for mix and tables for assets/ROTCE.Morgan Stanley | Investor Presentation Deck | 13 slides · Morgan Stanley
Conference presentation Investor relations Beat · What Is1 hit
05
The chart shows revenue growth across three regions (Americas, EMEA, Asia) over three time points (2010, 2018, 2023).Morgan Stanley | Investor Presentation Deck | 13 slides · Morgan Stanley
Conference presentation Investor relations Beat · What IsLoop · Benchmark Gap1 hit
09
Morgan Stanley | Investor Presentation Deck | 13 slidesMorgan Stanley | Investor Presentation Deck | 13 slides · Morgan Stanley
Conference presentation Investor relations Beat · What Could Be1 hit
11
Includes reconciliation table for Net Revenues and Pre-Tax Profit adjustments.Morgan Stanley | Investor Presentation Deck | 13 slides · Morgan Stanley
Conference presentation Investor relations Beat · New Bliss1 hit
05
NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slidesNeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · ProblemLoop · Golden Circle1 hit
08
The slide uses a standard comparison table format to contrast a competitor (Resmetirom) with the company's own asset (DA-1241).NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Pattern Hunter1 hit
13
Includes study design details for a multicenter, randomized, double-blind, placebo-controlled trial.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
16
The table highlights DA-1726's dual agonist mechanism (GLP-1R/GCGR) as a key differentiator against standard GLP-1 agonists.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Market SizeLoop · Golden Circle1 hit
20
Includes definitions for MAD, SAD, PK, PD, FPFV, and LPLV.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Market SizeLoop · Golden Circle1 hit
13
Includes a footnote citation for the methodology definitions.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
15
The slide shows baseline characteristics for a clinical trial, confirming that the treatment and placebo groups are well-matched.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
16
The table displays percentages for various categories of adverse events (AEs) and treatment-emergent adverse events (TEAEs).NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
33
Data includes adjusted means, 95% confidence intervals, p-values, and percentage differences for various motor and respiratory domains.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
05
The table compares NYCB's performance at two different dates (9/30/22 and 12/31/23) against a peer median as of 9/30/23.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations 1 hit
07
Includes non-GAAP reconciliations note and rounding note.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit
08
Includes non-GAAP adjustments and profitability metrics.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · FinancialsLoop · Cost Of Inaction1 hit